Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
99.58
+1.18 (1.20%)
Mar 9, 2026, 4:00 PM EDT - Market closed
Revolution Medicines Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | - | - | 11.58 | 35.38 | 29.39 | |
| Revenue Growth (YoY) | - | - | -67.27% | 20.38% | -31.62% | |
| Cost of Revenue | 987.33 | 592.23 | 423.14 | 253.07 | 186.95 | |
| Gross Profit | -987.33 | -592.23 | -411.56 | -217.69 | -157.56 | |
| Selling, General & Admin | 195.04 | 97.3 | 75.62 | 40.59 | 30.45 | |
| Operating Expenses | 195.04 | 97.3 | 75.62 | 40.59 | 30.45 | |
| Operating Income | -1,182 | -689.52 | -487.19 | -258.28 | -188.01 | |
| Interest Expense | -24.23 | - | - | - | -0.01 | |
| Interest & Investment Income | 90.69 | 86.88 | 47.48 | 9.15 | 0.93 | |
| Other Non Operating Income (Expenses) | -15.4 | 1.8 | -0.19 | - | - | |
| EBT Excluding Unusual Items | -1,131 | -600.85 | -439.89 | -249.13 | -187.09 | |
| Pretax Income | -1,131 | -600.85 | -439.89 | -249.13 | -187.09 | |
| Income Tax Expense | - | -0.75 | -3.52 | -0.42 | - | |
| Net Income | -1,131 | -600.09 | -436.37 | -248.71 | -187.09 | |
| Net Income to Common | -1,131 | -600.09 | -436.37 | -248.71 | -187.09 | |
| Shares Outstanding (Basic) | 190 | 168 | 113 | 81 | 73 | |
| Shares Outstanding (Diluted) | 190 | 168 | 113 | 81 | 73 | |
| Shares Change (YoY) | 13.35% | 48.24% | 40.34% | 10.74% | 32.68% | |
| EPS (Basic) | -5.95 | -3.58 | -3.86 | -3.08 | -2.57 | |
| EPS (Diluted) | -5.95 | -3.58 | -3.86 | -3.08 | -2.57 | |
| Free Cash Flow | -913.73 | -567.74 | -358.3 | -235.22 | -153.71 | |
| Free Cash Flow Per Share | -4.81 | -3.38 | -3.17 | -2.92 | -2.11 | |
| Operating Margin | - | - | -4207.12% | -730.01% | -639.70% | |
| Profit Margin | - | - | -3768.28% | -702.95% | -636.58% | |
| Free Cash Flow Margin | - | - | -3094.14% | -664.83% | -522.99% | |
| EBITDA | -1,175 | -683 | -482.18 | -254.34 | -184.96 | |
| D&A For EBITDA | 7.75 | 6.53 | 5.01 | 3.94 | 3.05 | |
| EBIT | -1,182 | -689.52 | -487.19 | -258.28 | -188.01 | |
| Revenue as Reported | - | - | 11.58 | 35.38 | 29.39 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.